Spoligotyping and drug sensitivity of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in the Arsi Zone of southeastern Ethiopia

Haile, Belete; Tafess, Ketema; Zewude, Aboma; Yenew, Bazezew; Siu, Gilman Kit-Hang; Ameni, Gobena

doi:10.1016/j.nmni.2019.100620

Cited by 12 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of MDR-TB in our study was 1.1% somewhat minimal compared with the National MDR-TB prevalence [ 3 ]. However, our result was in line with previous studies in our country [ 8 , 9 , 30 , 31 ]. High MDR-TB (4.3%) prevalence was reported from the National Tuberculosis Reference Laboratory and the seven Regional Laboratories among newly diagnosed TB patients [ 24 ].…”

Section: Discussionsupporting

confidence: 94%

Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia

et al. 2020

View full text Add to dashboard Cite

Introduction Multi-drug resistance is a major challenge in the control of tuberculosis. Despite newer modalities for diagnosis and treatment, people are still suffering from this disease. Understanding the common gene mutations conferring rifampicin and isoniazid resistance is crucial for the implementation of effective molecular tools at local and national levels. Hence, this study aimed to evaluate the molecular detection of rifampicin and isoniazid-resistant gene mutations in M . tuberculosis isolates in Addis Ababa, Ethiopia. Method Health Center-based cross-sectional study was conducted between January and September 2017 in Addis Ababa, Ethiopia. The collected sputum samples were processed for mycobacterial isolation and Region of difference 9 based polymerase chain reaction for species identification. To characterize the rifampicin and isoniazid-resistant M . tuberculosis isolates, a molecular genetic assay (GenoType MTBDR plus ) was used; the assay is based on DNA-STRIP technology. Result Culture positivity was confirmed in 82.6% (190/230) of smear-positive newly diagnosed pulmonary tuberculosis cases enrolled in the study. From 190 isolates 93.2% were sensitive for both rifampicin and isoniazid, and 6.8% of the isolates were resistant to at least one of the tested anti-TB drugs. Gene mutations were observed in all studied multidrug resistance-associated gene loci ( rpoB , katG , and inhA ). Two isolates exhibited heteroresistance, a mutated, as well as wild type sequences, were detected in the respective strains. MDR-TB case was observed in 1.1% (2/190) of the cases. All the MDR-TB cases were positive for HIV and found to have a history of prior hospital admission. Conclusion In our finding a relatively high prevalence of any drug resistance was observed and the overall prevalence of multidrug-resistant tuberculosis was 1.1%.The majority of drug-resistant isolates demonstrated common mutations. Heteroresistant strains were detected, signaling the existence of an M . tuberculosis population with variable responses to anti-tuberculosis drugs or of mixed infections.

show abstract

Section: Discussionsupporting

confidence: 94%

Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Tuberculosis (TB) is among the primary health problems, 1,2 particularly in lowincome countries, and is considered as the leading cause of death from a single infectious disease ranking above HIV/AIDS. [3][4][5][6][7][8][9] Worldwide, an estimated 10.0 million people felt ill with an estimated 1.4 million deaths in 2019. 10 Mycobacterium tuberculosis (Mtb) is a grievous pathogenic organism, 11 infecting nearly one-third of the world's population, where drug-resistant Mtb complex strains are expected to account for one third of all deaths due to TB.…”

Section: Introductionmentioning

confidence: 99%

“…Both MDR-and XDR-TB forms have exacerbated the spread of TB in developing countries. 7,14 Mtb drug resistance is among the key challenges in ending TB, 15 where the emergence of drug-resistant TB is delaying its control. 16 Resistance to INH reduces the probability of treatment success and increases the risk of acquiring resistance to other first-line drugs such as RIF, thereby increasing the risk of MDR-TB.…”

Section: Introductionmentioning

confidence: 99%

“…10 As in other developing countries, TB/HIV co-infection and the emergence of MDR-TB are becoming pressing challenges in the efforts to control TB in Ethiopia. 7,22 To handle this situation, currently, Ethiopia recommends GeneXpert MTB/RIF as the first-line of DST TB diagnosis and RIF resistance detection in facilities where this molecular diagnosis technique is available. Indeed, in Ethiopia, first-line DST is performed through GeneXpert and MTBDRplus LPA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Magnitude of Phenotypic and MTBDRplus Line Probe Assay First-Line Anti-Tuberculosis Drug Resistance Among Tuberculosis Patients; Northwest Ethiopia

Yigzaw¹,

Torrelles²,

Wang³

et al. 2021

IDR

View full text Add to dashboard Cite

Background: Mycobacterium tuberculosis (Mtb) drug resistance is a key challenge in ending TB. Objective: The study aimed to determine anti-TB drug resistance and compare the discordance between phenotypic and genotypic drug-susceptibility testing (DST). Methods: Prospective enrollment and sputum collection from patients suspected of active pulmonary TB from May 2018 to December 2019 at the University of Gondar Hospital. Phenotypic DST study for streptomycin, isoniazid, rifampin, and ethambutol was done by MGIT 360 SIRE Kit. Genotypic resistance for isoniazid and rifampin was performed by MTBDRplus v2 line probe assay (LPA) and compared to phenotypic drug resistance. Results: A total of 376 patients, median age 32 years, and 53.7% male were enrolled. Mtb was isolated from 126 patients. 106/126 (84%) patients were newly diagnosed with TB and 20 patients with prior TB treatment. Seventy (66.0%) were susceptible to all anti-TB drugs tested. Twenty-five (19.8%) of the isolates were resistant to isoniazid, 12 (9.5%) to rifampicin and six (5%) were multidrug resistant. Among previously treated TB patients, 4 (20.0%) and 5 (25.0%) were mono-resistant and poly-resistant, respectively. The sensitivity and specificity of LPA resistance for isoniazid were 94.4% and 100%, and for rifampin was 75.0% and 100%, respectively. Conclusion: The frequency of mono-and poly-drug resistance among both newly diagnosed and previously treated TB patients was high to the rest of the nation. MTBDRplus showed excellent concordance for isoniazid and rifampin. We concluded that DST should be performed for all patients to improve management and decrease spread of drug-resistant Mtb strains in the community.

show abstract

“…As described in Table 1 and Table S4, a total of 19 studies with 5,057 TB patients (3504 culture, line probe assay and/or GeneXpertMTB/RIF assay positive Mtb isolates) were included for final analysis [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Prevalence of drug resistance-conferring mutations associated with isoniazid and rifampicin resistantMycobacterium tuberculosisin Ethiopia: A systematic review and meta-analysis

Reta

Alemnew

Abate

2020

Preprint

View full text Add to dashboard Cite

Background: Drug resistance tuberculosis (DR-TB) continues to be a major public health threat globally. Due to the development of many rapid molecular diagnostic tools to detect gene mutations in M.tuberculosis (Mtb), specific genes conferring resistance to different anti-TB drugs have been identified. The aim of this meta-analysis was to assess the prevalence of the gene mutations associated with rifampicin (RIF) and isoniazid (INH) resistant Mtb in Ethiopia. Methods: Using PRISMA guideline, we systematically searched a literature on PubMed/MEDLINE, Web of Science, Scopus electronic databases, Cochrane library, and other database sources. The data analysis was done using STATA 11. The pooled prevalence of the gene mutations associated with resistance to RIF and INH were estimated using the random effect model. Heterogeneity was measured by the I2 statistical test, and the publication bias through the funnel plot and the Eggers regression test. Results: Among all antimycobacterial resistance tested TB patients, prevalence of resistance to any anti-TB drug was 31.3%, while multidrug resistance TB (MDR-TB), any RIF and INH resistance were 22.2%, 24.9%, and 27.9%, respectively. In total, 909 (95.8%) of 949 INH resistant Mtb isolates had detectable gene mutation in katG315 and 5.9% in the inhA gene. The meta-analysis derived an estimated pooled prevalence of katGMUT1(S315T1) in INH resistant Mtb was 89.18% (95%CI 81.94-96.43%), while a pooled inhAMUT1 (C15T) resistant Mtb prevalence was 77.48% (95% CI 57.84-97.13%). Besides, 769 (90.8%) of 847 RIF resistant strains had detectable rpoB gene mutation, commonly in rpoBMUT3(S531L) probe (550 cases). The meta-analysis resulting a pooled rpoBMUT3(S531L) resistant Mtb prevalence of 74.20 % (95%CI 66.39-82.00%). Conclusions: RIF resistant Mtb isolates were spread widely, mainly with S531L mutation. Similarly, INH resistant Mtb isolates were spread with S315T1 and C15T mutations. It is significant to detect S531L among RIF resistant and S315T1 and C15T mutations among INH resistant isolates as it may be a determinant for subsequent development of MDR-TB. Rapid diagnosis of RIF and INH resistant Mtb strains in TB patients would expedite modification of treatment regimens, and proper infection control interventions could be taken on time to reduce the risk of further development and transmission of MDR-TB.

show abstract

Spoligotyping and drug sensitivity of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in the Arsi Zone of southeastern Ethiopia

Cited by 12 publications

References 35 publications

Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia

Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia

Magnitude of Phenotypic and MTBDRplus Line Probe Assay First-Line Anti-Tuberculosis Drug Resistance Among Tuberculosis Patients; Northwest Ethiopia

Prevalence of drug resistance-conferring mutations associated with isoniazid and rifampicin resistantMycobacterium tuberculosisin Ethiopia: A systematic review and meta-analysis

Contact Info

Product

Resources

About